Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal

Selected Publication:

Grimminger, F; Rose, F; Ghofrani, HA; Schermuly, RT; Weissmann, N; Olschewski, H; Walmrath, D; Seeger, W.
Inhalative strategies for improvement of pulmonary hemodynamics and gas exchange in sepsis and severe pulmonary hypertension
Z Kardiol. 2000; 89(6):477-484 Doi: 10.1007/s003920070218
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Co-authors Med Uni Graz
Olschewski Horst
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
Chronic pulmonary hypertension and septic lung failure display different clinical features resulting in severe disturbances in the pulmonary circulation. In these diseases, the pulmonary bloodflow is impaired by a pathologic constriction of blood vessels that may lead to right ventricular overloading as well as serious worsening of gas exchange mainly caused by ventilation/perfusion mismatch. Various mechanisms deteriorating the vascular function may induce both an irreversible and a reversible contraction of pulmonary vessels, respectively. Two pharmacological approaches exist to reduce the vascular resistance: Reduction of the increased vascular tone by relaxation of vascular smooth muscle cells (effect of vasodilators). Inhibition of thrombus-mediated obliteration of the lung perfusion by use of anticoagulant and fibrinolytic drugs. Prevention of the structural reorganization of pulmonary vessels (vascular remodeling) by use of vasodilators with anti-inflammatory and anti-proliferative potency such as prostanoids. The systemic (intravenous or oral) application of vasodilative agents in sepsis and chronic pulmonary hypertension has, however, important side effects: Antagonism of the hypoxic pulmonary vasoconstriction aggravates the ventilation/perfusion mismatch (decrease in arterial oxygenation). Side effects of these vasodilators (systemic hypotension). The inhalative route of application is superior because of the pulmonary enrichment of the applied agent (pulmonary selectivity). Furthermore, a preferential deposition in the well-ventilated areas of the lung is achieved (intrapulmonary selectivity). Thus, the decrease in pulmonary-vascular resistance is paralleled by both optimized ventilation-perfusion matching and subsequently improved gas exchange. First clinical studies with inhaled nitric oxide and aerosolized prostacyclin have been performed in intubated and mechanically ventilated patients with septic lung failure. At present, the use of the long-acting prostacyclin analogue ilomedin for ambulant treatment of patients with chronic pulmonary hypertension is under investigation.
Find related publications in this database (using NLM MeSH Indexing)
Acute Disease -
Aerosols -
Antihypertensive Agents - administration and dosage
Clinical Trials - administration and dosage
Epoprostenol - administration and dosage
Hemodynamic Processes - administration and dosage
Humans - administration and dosage
Hypertension, Pulmonary - drug therapy
Nitric Oxide - administration and dosage
Pulmonary Circulation - administration and dosage
Pulmonary Gas Exchange - administration and dosage
Respiratory Distress Syndrome, Adult - drug therapy
Respiratory Therapy - drug therapy
Sepsis - drug therapy
Time Factors - drug therapy
Vasodilator Agents - administration and dosage

Find related publications in this database (Keywords)
acute/adult respiratory distress syndrome pulmonary hypertension
inhalative therapy
sepsis-nitric oxide
prostacyclin-ARDS and pulmonary hypertension
new aspects of the inhalative therapy
© Med Uni GrazImprint